ArticleLung2016

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.

Wim A Wuyts et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.